Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Single protein promotes resistance to widely used anti-estrogen drugs

02.07.2012
Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women.

In the July 1 issue of Cancer Research, the scientists say glucose-regulated protein 78 (GRP78), activated as breast cells undergo stress induced by the agents tamoxifen and fulvestrant, turns off apoptosis, a cell death response, and turns on autophagy. In autophagy, the cell "eats" and digests components within the cell body that have been harmed by the drugs, thus providing a blast of nutrients needed to maintain life.

The finding suggests that a novel agent that inhibits GRP78 might provide a solution for the tens of thousands of women who develop resistance to anti-estrogen drugs. While more than 70 percent of breast cancers express estrogen receptors that fuel growth of cancer, about one-third of these cases fail to be cured by therapies that target this receptor.

"Since GRP78 plays such an important role in drug resistance, it would be of great benefit to develop agents that target this protein," says the study's lead author, Katherine Cook, Ph.D., a postdoctoral investigator in the lab of Robert Clarke, Ph.D., D.Sc., professor of oncology and Dean for Research at Georgetown University Medical Center. Clarke is the study's senior author.

She adds that several GRP78 inhibitors have already been developed and are already being tested, but not yet at the level of human clinical trials.

The study is not only the first to show that GRP78 is a regulator of resistance to tamoxifen and fulvestrant, it is also the first to reveal the mechanism by which GRP78 directly controls autophagy, says Clarke.

"Why estrogen-receptor positive breast tumors fail to respond, or respond initially and progress upon acquiring resistance to these agents, has been largely unknown, " he says. "The novel signaling that we have uncovered could have high translational impact and bring a new and important perspective to the molecular crosstalk between cell stress, apoptosis, and autophagy."

This research is a continuation of a string of studies on anti-estrogen resistance by Clarke, Cook, and their collaborators at Georgetown.

A paper published March 15 in Cancer Research, for example, described how a program known as the "unfolded protein response" or UPR, is activated in breast cells treated with the therapies once these cells sense stress. This response is activated when there is an accumulation of unfolded or misfolded proteins within the cell.

"Since cancers often grow rapidly, tumors may lack enough energy to properly fold proteins into the correct orientation. These misfolded proteins accumulate in the cell and trigger UPR," says Cook. "In normal cells, UPR is protective and if the stimuli lasts for an extended period of time UPR becomes pro-death. But we have found cancers use the UPR to promote survival."

In this study, the scientists zeroed in on GRP78 as the master regulator of UPR, thus promoting anti-estrogen resistance. It does this by preventing stressed cells to initiate programmed cell death, and by stimulating autophagy, which clears cells of the misfolded proteins while providing beneficial nutrition to the cell.

When the scientists inhibited GRP78 in anti-estrogen resistant cells, they promoted cell death and inhibited autophagy, resulting in increased numbers of dead cells.

They also found that GRP78 does not play a role in breast cancers that never responded to anti-estrogen therapy, indicating that initial resistance and acquired resistance represent separate biological phenomenon. "This observation is consistent with the emerging concept that acquired resistance may be an adaptive response," Cook says.

She also notes that elevated GRP78 has been found in different cancer types, in addition to breast cancer, and in resistance to several different chemotherapy treatments.

"The basic principle we establish of using GRP78 to integrate the cellular functions of apoptosis and autophagy raises the provocative question that this signaling may be widely applicable and represent a major stress response," Cook says.

Other investigators who contributed to the research are Ayesha N. Shajahan Ph.D., Anni Wärri Ph.D., Lu Jin M.S., and Leena A. Hilakivi-Clarke Ph.D., of the department of oncology at Georgetown Lombardi Comprehensive Medical Center. The authors report having no personal financial interests related to the study. This research was supported by NCI grants Clarke (R01-CA131465 and U54-CA149147). Cook was supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) training grant (5-T32-CA009686), and she is a recipient of a Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (BC112023).

About Georgetown Lombardi Comprehensive Cancer Center

Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and MedStar Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.

Karen Mallet | EurekAlert!
Further information:
http://www.georgetown.edu

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>